Ebola virus monoclonal antibodies

Ebola virus causes severe haemorrhagic fever with a high fatality rate. Human-to-human transmission is through contact with body fluids, and recent well-documented outbreaks occurred during 2013–2015 in West Africa. The natural reservoir of this RNA virus is thought to be bats, and several strains of the virus have emerged, including the Zaire, Sudan and Bundi variants.

ViroStat has now introduced new sets of monoclonal antibodies to two of the significant antigens of this virus; nucleoprotein (NP) and VP40. These antibodies function in enzyme-linked immunosorbent assay (ELISA) and Western blot with both the Zaire and Sudan antigen sequences. As such, they offer powerful tools for the development of rapid immunoassays to aid in the detection of this virus.

ViroStat is a primary manufacturer of infectious disease antigens and antibodies, supplying researchers and manufacturers since 1985. Specialties include high-affinity antibodies to influenza A and B, respiratory syncytial virus (RSV) and group A Streptococcus for use in rapid lateral-flow devices as well as antibodies to foodborne pathogens and toxins.

Data sheets on the new Ebola antibodies can be downloaded from the company’s website.




Other news

Upcoming Events

The Fundamentals of Cell Culture: Key Principles and Practice

Public Health England, Porton Down SP4 0JG
20-23 March 2018

British Society for Microbial Technology Annual Scientific Conference

Public Health England, Colindale, London
18 May 2018

Advanced Cell Culture: A Practical Approach

Coin Street Conference Centre, 108 Stamford Street, Lambeth, London SE1 9NH
8 June 2018

Pathology Horizons 2018 Conference

Lough Erne Resort, Co. Fermanagh, Northern Ireland
September 13-15

Microbe 2018

Hilton Hotel, Sheffield
21-23 September 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Feb 2018

Experience drives revolution... the NanoZoomer S360

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.